New automated technology for small diameter vascular grafts fabrication developed by Cells for Cells

The study, conducted by the Chilean biotech company Cells for Cells was published in Nature Communications journal. The automated approach allows the assembly of bio-inspired structural configurations enabling the fabrication of small-bore grafts that exhibit mechanical response and compliance of human coronary arteries. Global deaths attributed to cardiovascular disease are expected to reach 22.2 million […]

A Chilean cell-based clinical trial in osteoarthritis reveals the superiority of repetitive MSC injections to Hyaluronic Acid treatment

The study, made by the Chilean biotech company Cells for Cells and Universidad de los Andes Clinical Center, was published in STEM CELLS Translational Medicine journal. The work shows that patients with knee osteoarthritis treated with the allogeneic umbilical cord MSC-based therapy branded as CELLISTEM® OA, experienced a significant improvement in pain reduction, increased mobility […]

Strong attendance, new regulation and growing regional interest mark the annual meeting of the Brazilian Association for Cell Therapy (ABTCEL)

A total of 277 attendees, a record number of 128 selected abstracts and 56 national and international speakers were the figures bolstering up the growing interest for cell therapy in the SCA region. ISCT participated in this successful event, in Sao Paulo, through a joint session focusing on clinical applications. The ISCT awards for best […]

Cardiac risk in Chileans How do we help to face this challenge?

At the end of January, the Ministry of Health announced the second delivery of the results of the National Health Survey (ENS). Among other indicators, it reveals that 25.5 percent of the Chilean population is in the category of high cardiovascular risk. The are many factors and, without a doubt, it is an important challenge […]